Menu
Recruiting NCT06487832

Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness

No phase Interventional Normal Weight Overweight and Obesity Insulin Sensitivity Insulin Resistance

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Subcutaneous GLP1-RA, Subcutaneous placebo.
Who it may be relevant to
Registry conditions: Normal Weight, Overweight and Obesity, Insulin Sensitivity, Insulin Resistance. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Germany
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Impact of the Incretin System on Brain Insulin Sensitivity in Humans with Normal Weight, Overweight and Obesity

Overview

The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design. To this end, investigators will compare the effect of the administration of semaglutide versus placebo, followed by an fMRI with administration of intranasal insulin or placebo.

Detailed description

Investigate the effect of the GLP1 receptor agonist (i.e. 0.25 mg semaglutide) vs. placebo on the brain using functional magnetic resonance imaging (fMRI) in combination with 160IU intranasal insulin vs. placebo administration in healthy male and female participants of normal-weight and overweight/obesity. Participants will furthermore undergo tasks that assess cognitive functions and eating behavior. Brain insulin responsiveness (primary outcome) is defined as the cerebral response to intranasal insulin compared to placebo by means of cerebral blood flow and resting-state BOLD measurements. Secondary outcomes include diffusion weighted imaging, neural food cue reactivity, cognitive functions and metabolic predictors.

Interventions

  • Other Subcutaneous GLP1-RA
    Subcutaneous administration of semaglutide
  • Other Subcutaneous placebo
    Subcutaneous administration of NaCl

Primary outcome measures

  • Cerebral response after insulin compared to placebo nasal spray [Time frame: 24 hours after semaglutide or placebo administration]
Secondary outcome measures (6)
  • Neural food-cue reactivity after insulin compared to placebo nasal spray [Time frame: 24 hours after semaglutide or placebo administration]
  • Diffusion-weighted imaging (DWI) [Time frame: 24 hours after semaglutide or placebo administration]
  • Heart rate variability (HRV) [Time frame: 24 hours after semaglutide or placebo administration]
  • Change in subjective feeling of hunger and food craving [Time frame: 24 hours after semaglutide or placebo administration]
  • Change in mood [Time frame: 24 hours after semaglutide or placebo administration]
  • Performance during cognitive tests [Time frame: 24 hours after semaglutide or placebo administration]

Eligibility criteria

Inclusion criteria

  • BMI between 18.5 and 24.9 kg/m2; and between 27.5 kg/m2 and 40 kg/m2
  • Written consent to participate in the study
  • Written consent to be informed about incidental findings

Exclusion criteria

  • Type 1 or type 2 diabetes, LADA, MODY, or cardiovascular diseases such as chronic heart failure, myocardial infarction, status post stroke
  • BMI < 18.5 or > 40 kg/m2
  • Persons who cannot legally give consent
  • Pregnancy or lactation
  • History of severe mental or somatic disorders including neurological diseases (incl. epileptic seizures)
  • Taking psychotropic drugs
  • Chronic diseases or medication that influence glucose metabolism
  • Regular use of analgesic drugs
  • Previous bariatric surgery
  • Known allergy against one or more of the used agents
  • Acute infection and/or antibiotic treatment within the last 4 weeks
  • Hemoglobin values less than 10.5 g/dl for women, less than 11.5 g/dl for men
  • Other diseases that in the opinion of the investigator may jeopardize the success of the study or indicate a risk to the volunteer
  • Participation in a lifestyle intervention study or a pharmaceutical study within the last 30 days
  • Metal implants which cannot be removed as pacemakers, artificial heart valve, electrical devices as insulin pumps, large tattoos, retainer over more than 4 teeth, contraceptive coil, implanted magnetic metal parts as screws or plates after a surgery
  • Persons with claustrophobia
  • Persons with tinnitus
  • Weight loss or gain of >5% in the last 3 months
  • Pancreatic diseases
  • History or family history of multiple endocrine neoplasia (MEN2) or medullary thyroid cancer
  • History of malignant thyroid disease
  • History of malignant disease in the past 5 years
  • Surgery in the last three months
  • Chronic tobacco use of more than 10 cigarettes/day
  • Women who do not consent to refrain from breastfeeding until 2 months after the end of the study
  • Women of childbearing age who do not consent to use safe method of contraception from 28 days before until 2 months after the end of the study or refrain from heterosexual intercourse during this time
  • Women of childbearing age who do not consent to take a pregnancy test

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Single blind
Primary purpose
Basic science

Study locations

Germany · 1 center
  • University Clinic Tubingen, Department of Internal Medicine IV — Tübingen

Identifiers

NCT: NCT06487832 · 065/2024BO1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗